Phases précoces tumeurs solides
BET115521
A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma(NMC) and other cancers.
Paris
CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides
BI 1336.1
A First-in Human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 836880 administered by repeated intravenous infusions in patients with solid tumors.
Paris
CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides
I4T-MC-JVDF
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab plus Pembrolizumab in Patients with Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer.
Paris
CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides
BI1280.18
An Open Label, Phase Ib Dose-escalation Study Evaluating the Safety and Tolerability of BI 836845 and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive Breast Cancer, Followed by Expansion Cohorts.
Paris
FRANCESCO RICCI
Phases précoces tumeurs solides
D3610C00001
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.
Paris
MARIE PAULE SABLIN
Phases précoces tumeurs solides
TG4001.12
A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies and expansion cohort to oropharyngeal squamous cell carcinoma of the head and neck (SCCHN)
Paris
CHRISTOPHE LE TOURNEAU
Sein métastatique RH+
AIPAC
AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel
Saint-Cloud
ETIENNE BRAIN
Sein métastatique RH+
BYLieve (CBYL719X402)
A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment
Saint-Cloud
FLORENCE LEREBOURS
Phases précoces tumeurs solides
CA009-002 (Immuno)
A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy;of anti-GITR Monoclonal Antibody (BMS-986156) Administered Alone and in Combination;with Nivolumab (BMS-936558, anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors
Paris
EMANUELA ROMANO
Phases précoces tumeurs solides
CA017-003
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors.
Paris
CHRISTOPHE LE TOURNEAU